WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer.

Inflammatory breast cancer (IBC) is the most lethal form of locally advanced breast cancer. We have found that WISP3 is lost in 80% of human IBC tumors and that it has growth- and angiogenesis-inhibitory functions in breast cancer in vitro and in vivo. WISP3 is a cysteine-rich, putatively secreted protein that belongs to the CCN family. It contains a signal peptide at the N-terminus and four highly conserved motifs. Here, for the first time, we investigate the function of WISP3 protein in relationship to its structural features. We found that WISP3 is secreted into the conditioned media and into the lumens of normal breast ducts. Once secreted, WISP3 was able to decrease, directly or through induction of other molecule(s), the IGF-1-induced activation of the IGF-IR, and two of its main downstream signaling molecules, IRS1 and ERK-1/2, in SUM149 IBC cells. Furthermore, WISP3 containing conditioned media decreased the growth rate of SUM149 cells. This work sheds light into the mechanism of WISP3 function by demonstrating that it is secreted and that, once in the extracellular media, it induces a series of molecular events that leads to modulation of IGF-IR signaling pathways and cellular growth in IBC cells.

[1]  E. Surmacz.  Function of the IGF-I Receptor in Breast Cancer , 2004, Journal of Mammary Gland Biology and Neoplasia.

[2]  W. Ruan,et al.  IGF-I: An Essential Factor in Terminal End Bud Formation and Ductal Morphogenesis , 2004, Journal of Mammary Gland Biology and Neoplasia.

[3]  A. Levine,et al.  Overexpression of WISP-1 Down-regulated Motility and Invasion of Lung Cancer Cells through Inhibition of Rac Activation* , 2003, The Journal of Biological Chemistry.

[4]  Rey-Huei Chen,et al.  Molecular interpretation of ERK signal duration by immediate early gene products , 2002, Nature Cell Biology.

[5]  S. Merajver,et al.  WISP3 is a novel tumor suppressor gene of inflammatory breast cancer , 2002, Oncogene.

[6]  H. Senn,et al.  Insulin-like growth factors and cancer. , 2002, The Lancet. Oncology.

[7]  R. McPherson,et al.  The role of mitogen-activated protein (MAP) kinase in breast cancer , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[8]  R. Elashoff,et al.  Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. , 2001, Cancer research.

[9]  Carl W. Miller,et al.  Cyr61, a Member of CCN Family, Is a Tumor Suppressor in Non-Small Cell Lung Cancer* , 2001, The Journal of Biological Chemistry.

[10]  M. Herlyn,et al.  Insulin-like Growth Factor-1 Induces Survival and Growth of Biologically Early Melanoma Cells through Both the Mitogen-activated Protein Kinase and β-Catenin Pathways , 2001 .

[11]  M. Camps,et al.  The nucleus, a site for signal termination by sequestration and inactivation of p42/p44 MAP kinases. , 2001, Journal of cell science.

[12]  S. Andò,et al.  Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. , 2001, Cancer research.

[13]  J. Pouysségur,et al.  Spatiotemporal regulation of the p42/p44 MAPK pathway , 2001, Biology of the cell.

[14]  T. Holak,et al.  The interaction of insulin‐like growth factor‐I with the N‐terminal domain of IGFBP‐5 , 2001, The EMBO journal.

[15]  B. Perbal.  NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues , 2001, Molecular pathology : MP.

[16]  M. Herlyn,et al.  Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. , 2001, Cancer research.

[17]  S. Merajver,et al.  RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. , 2000, Cancer research.

[18]  W. Willett,et al.  Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. , 2000, Cancer research.

[19]  R. Baserga.  The IGF-I receptor in cancer research. , 1999, Experimental cell research.

[20]  D. Yee,et al.  IRS-1 expression and activation are not sufficient to activate downstream pathways and enable IGF-I growth response in estrogen receptor negative breast cancer cells. , 1999, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[21]  R. Pauli,et al.  Mutations in the CCN gene family member WISP3 cause progressive pseudorheumatoid dysplasia , 1999, Nature Genetics.

[22]  S. Merajver,et al.  A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  S. Hilsenbeck,et al.  Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. , 1999, Molecular endocrinology.

[24]  E. Wilson,et al.  Binding properties and distribution of insulin-like growth factor binding protein-related protein 3 (IGFBP-rP3/NovH), an additional member of the IGFBP Superfamily. , 1999, The Journal of clinical endocrinology and metabolism.

[25]  D. Botstein,et al.  WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  D. Yee,et al.  Insulin Receptor Substrate-1 is the Predominant Signaling Molecule Activated by Insulin-like Growth Factor-I, Insulin, and Interleukin-4 in Estrogen Receptor-positive Human Breast Cancer Cells* , 1998, The Journal of Biological Chemistry.

[27]  R. Baserga,et al.  The Role of the Insulin‐like Growth Factor I Receptor in Transformation and Apoptosis , 1998, Annals of the New York Academy of Sciences.

[28]  N. Webster,et al.  Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. , 1998, Cancer research.

[29]  E. Wilson,et al.  Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs): characterization of connective tissue growth factor as a member of the IGFBP superfamily. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  P. Glazer,et al.  Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. , 1997, Cancer research.

[31]  S. Merajver,et al.  Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Hilsenbeck,et al.  Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  L. Lau,et al.  Cyr61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion , 1996, Molecular and cellular biology.

[34]  B. Weber,et al.  Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. , 1993, Cancer research.

[35]  D. Kerr,et al.  The response of breast cancer cells to steroid and peptide growth factors. , 1992, Anticancer research.

[36]  G. Hortobagyi,et al.  Inflammatory breast cancer: a review. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Key,et al.  Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[38]  J. Bonneterre,et al.  Characterization of insulin-like growth factor 1 receptors (IGF1-R) in human breast cancer cell lines. , 1989, Bulletin du cancer.

[39]  S. Steinberg,et al.  Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. , 1987, Cancer research.

[40]  大橋 広文.  Inflammatory carcinoma of the breastの1例 (乳癌(小特集)) , 1968 .

[41]  DvTsg,et al.  The Twisted gastrulation family of proteins, together with the IGFBP and CCN families, comprise the TIC superfamily of cysteine rich secreted factors , 2022 .